Escherichia coli BL21(DE3) Genome sequencing and assembly. Escherichia coli BL21(DE3)

Gram-negative Outer Membrane Vesicles OMVs can be exploited in the use as highly effective vaccine platform. However, some optimization is required, including the reduction of the number of endogenous proteins, the increase of the loading capacity with respect to heterologous antigens, the enhancement of productivity in terms of number of vesicles per culture volume. In this work, we describe the use of Synthetic Biology to create a derivative of Escherichia coli BL21(DE3) releasing proteome-minimized OMVs.